A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer's Disease

Grants and Contracts Details

StatusFinished
Effective start/end date1/24/24 → 4/23/24

Funding

  • Pharmaceutical Research Associates: $3,000.00